PB103 / Chongqing Precision Biotech - LARVOL DELTA

Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients (clinicaltrials.gov) - P1/2 | N=24 | Recruiting | Sponsor: Precision Biotech Taiwan Corp. | Trial completion date: Dec 2024 ➔ Dec 2027 | Trial primary completion date: Dec 2024 ➔ Dec 2027

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HLA-B • HLA-C • HLA-DRB1

Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients (clinicaltrials.gov) - P1/2 | N=24 | Recruiting | Sponsor: Precision Biotech Taiwan Corp. | Trial primary completion date: Jun 2022 ➔ Dec 2024

Combination therapy • Trial primary completion date • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HLA-B • HLA-C • HLA-DRB1